SecBot SecBot
6-K ·Filed Jun 24, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago SEC0001395064-26-000183
Notable filing: 6-K
Actionable Insight • Neutral

Monitor Takeda's next quarterly earnings for any strategic shifts under the new CEO, particularly around the three major launches mentioned in forward-looking commentary. The CEO transition was well-telegraphed over 18 months, so no immediate stock reaction is expected.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.72
T+0 close · Jun 24, 2026 · via day close
Latest settled
+21.18%
T+60 · $19.05
Vs SPY
+18.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 24 $15.72entry
  2. T+1 · 5mo ago −0.45%α −0.59% · $15.65
  3. T+5 · 5mo ago +1.46%α −0.24% · $15.95
  4. T+20 · 4mo ago +7.32%α +5.38% · $16.87
  5. T+60 · 2mo ago +21.18%α +18.35% · $19.05
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Takeda announced the official appointment of Julie Kim as Representative Director, President & CEO, completing an 18-month CEO transition. Former CEO Christophe Weber retired, and three new external directors were elected to the Board. The filing is a routine leadership succession announcement with no financial data or material operational changes reported.

Key Facts

  • Julie Kim appointed Representative Director, President & CEO effective June 24, 2026
  • Former CEO Christophe Weber retired after 12 years
  • Three new external directors elected: Bruce Broussard, Koichiro Kimura, Dr. Paul Stoffels
  • Board now has 8 external directors out of 11 total members
  • Audit, Nomination, and Compensation Committees composed solely of external directors
  • No financial figures, guidance, or material operational changes reported

Financial Impact

No financial impact reported in this filing

Risk Factors

  • Execution risk on pipeline launches under new leadership
  • Potential strategic pivot under new CEO not yet quantifiable

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000183
Document: form6k-2_062426.htm0001395064-26-000183
Document: 0001395064-26-000183-index-headers.html0001395064-26-000183
Document: 0001395064-26-000183-index.html0001395064-26-000183
Document: 0001395064-26-000183.txt0001395064-26-000183

Track record

18 reports on TAK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
  2. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  3. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  4. Oct 29, 202618d ago 6-K Neutral 4/10 No price data
  5. Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
  6. Sep 14, 20269w ago 6-K Bullish 7/10 Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
  7. Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
  8. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
  9. Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 3/10 Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (9h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026